175 related articles for article (PubMed ID: 36275670)
21. Evaluation of PD-L1, tumor-infiltrating lymphocytes, and CD8+ and FOXP3+ immune cells in HER2-positive breast cancer treated with neoadjuvant therapies.
Zhao J; Meisel J; Guo Y; Nahta R; Hsieh KL; Peng L; Wei Z; O'Regan R; Li X
Breast Cancer Res Treat; 2020 Oct; 183(3):599-606. PubMed ID: 32715443
[TBL] [Abstract][Full Text] [Related]
22. Neoadjuvant Chemoimmunotherapy Increases Tumor Immune Lymphocytes Infiltration in Resectable Non-small Cell Lung Cancer.
Chen T; Cao Z; Sun Y; Huang J; Shen S; Jin Y; Jiang L; Wen F; Zhao X; Zhang D; Chen Y; Huang M; Chen H; Lu S; Li Z
Ann Surg Oncol; 2023 Nov; 30(12):7549-7560. PubMed ID: 37587362
[TBL] [Abstract][Full Text] [Related]
23. Tumor microenvironment remodeling after neoadjuvant immunotherapy in non-small cell lung cancer revealed by single-cell RNA sequencing.
Hu J; Zhang L; Xia H; Yan Y; Zhu X; Sun F; Sun L; Li S; Li D; Wang J; Han Y; Zhang J; Bian D; Yu H; Chen Y; Fan P; Ma Q; Jiang G; Wang C; Zhang P
Genome Med; 2023 Mar; 15(1):14. PubMed ID: 36869384
[TBL] [Abstract][Full Text] [Related]
24. T-cell subsets and cytokines are indicative of neoadjuvant chemoimmunotherapy responses in NSCLC.
Yi L; Xu Z; Ma T; Wang C; Wei P; Xiao B; Zhang H; Che N; Liu Z; Han Y
Cancer Immunol Immunother; 2024 Apr; 73(6):99. PubMed ID: 38619623
[TBL] [Abstract][Full Text] [Related]
25. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
26. Circulating tumor DNA predicts neoadjuvant immunotherapy efficacy and recurrence-free survival in surgical non-small cell lung cancer patients.
Yue D; Liu W; Chen C; Zhang T; Ma Y; Cui L; Gu Y; Bei T; Zhao X; Zhang B; Bai Y; Romero A; Xu-Welliver M; Wang C; Zhang Z; Zhang B
Transl Lung Cancer Res; 2022 Feb; 11(2):263-276. PubMed ID: 35280315
[TBL] [Abstract][Full Text] [Related]
27. Tumor microenvironment(TME) and single-source dual-energy CT(ssDECT) on assessment of inconformity between RECIST1.1 and pathological remission in neoadjuvant immunotherapy of NSCLC.
Sun C; Ma X; Meng F; Chen X; Wang X; Sun W; Xu Y; He H; Zhang H; Ma K
Neoplasia; 2024 Apr; 50():100977. PubMed ID: 38354688
[TBL] [Abstract][Full Text] [Related]
28. Genomic features and tumor immune microenvironment alteration in NSCLC treated with neoadjuvant PD-1 blockade.
Wang S; Yuan P; Mao B; Li N; Ying J; Tao X; Tang W; Zhang L; Geng X; Zhang F; Xue Q; Wu L; Zhang H; Gao S; He J
NPJ Precis Oncol; 2022 Jan; 6(1):2. PubMed ID: 35027673
[TBL] [Abstract][Full Text] [Related]
29. A high CD8 to FOXP3 ratio in the tumor stroma and expression of PTEN in tumor cells are associated with improved survival in non-metastatic triple-negative breast carcinoma.
Tavares MC; Sampaio CD; Lima GE; Andrade VP; Gonçalves DG; Macedo MP; Cordeiro de Lima VC
BMC Cancer; 2021 Aug; 21(1):901. PubMed ID: 34362334
[TBL] [Abstract][Full Text] [Related]
30. Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small-cell lung cancer (Nsq-NSCLC) with PD-L1-high expression using real-world data.
Pérol M; Felip E; Dafni U; Polito L; Pal N; Tsourti Z; Ton TGN; Merritt D; Morris S; Stahel R; Peters S
Ann Oncol; 2022 May; 33(5):511-521. PubMed ID: 35218887
[TBL] [Abstract][Full Text] [Related]
31. A Support Vector Machine Based on Liquid Immune Profiling Predicts Major Pathological Response to Chemotherapy Plus Anti-PD-1/PD-L1 as a Neoadjuvant Treatment for Patients With Resectable Non-Small Cell Lung Cancer.
Peng J; Zou D; Han L; Yin Z; Hu X
Front Immunol; 2021; 12():778276. PubMed ID: 35095850
[TBL] [Abstract][Full Text] [Related]
32. Different
Ye ZH; Long H; Zhao ZR
J Immunol Res; 2022; 2022():8513747. PubMed ID: 35528615
[TBL] [Abstract][Full Text] [Related]
33. Association of a novel 27-gene immuno-oncology assay with efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer.
Ranganath H; Jain AL; Smith JR; Ryder J; Chaudry A; Miller E; Hare F; Valasareddy P; Seitz RS; Hout DR; Varga MG; Schweitzer BL; Nielsen TJ; Mullins J; Ross DT; Gandara DR; Vidal GA
BMC Cancer; 2022 Apr; 22(1):407. PubMed ID: 35421940
[TBL] [Abstract][Full Text] [Related]
34. Clinicopathological significance of the immunologic signature (PDL1, FOXP3+ Tregs, TILs) in early stage triple-negative breast cancer treated with neoadjuvant chemotherapy.
Abdelrahman AE; Rashed HE; MostafaToam ; Omar A; Abdelhamid MI; Matar I
Ann Diagn Pathol; 2021 Apr; 51():151676. PubMed ID: 33360026
[TBL] [Abstract][Full Text] [Related]
35. Neoadjuvant immunotherapy combined with chemotherapy significantly improved patients' overall survival when compared with neoadjuvant chemotherapy in non-small cell lung cancer: A cohort study.
Dai F; Wu X; Wang X; Li K; Wang Y; Shen C; Zhou J; Niu H; Deng B; Tan Q; Wang R; Guo W
Front Oncol; 2022; 12():1022123. PubMed ID: 36353552
[TBL] [Abstract][Full Text] [Related]
36. T cells, B cells, and PD-L1 expression in esophageal and gastric adenocarcinoma before and after neoadjuvant chemotherapy: relationship with histopathological response and survival.
Christina Svensson M; Lindén A; Nygaard J; Borg D; Hedner C; Nodin B; Leandersson K; Jirström K
Oncoimmunology; 2021 May; 10(1):1921443. PubMed ID: 34104541
[TBL] [Abstract][Full Text] [Related]
37. Short-term outcome of neoadjuvant immunotherapy and chemotherapy in non-small cell lung cancer: A systematic review and meta-analysis.
Zhang C; Hong HZ; Wu YL; Zhong WZ
JTCVS Open; 2021 Dec; 8():588-607. PubMed ID: 36004199
[TBL] [Abstract][Full Text] [Related]
38. The implications of clinical risk factors, CAR index, and compositional changes of immune cells on hyperprogressive disease in non-small cell lung cancer patients receiving immunotherapy.
Kim SR; Chun SH; Kim JR; Kim SY; Seo JY; Jung CK; Gil BM; Kim JO; Ko YH; Woo IS; Shim BY; Hong SH; Kang JH
BMC Cancer; 2021 Jan; 21(1):19. PubMed ID: 33402127
[TBL] [Abstract][Full Text] [Related]
39. Multidimensional profiling depicts infiltrating immune cell heterogeneity in the tumor microenvironment of stage IA non-small cell lung cancer.
Duan J; Lv G; Zhu N; Chen X; Shao Y; Liu Y; Zhao W; Shi Y
Thorac Cancer; 2022 Apr; 13(7):947-955. PubMed ID: 35150094
[TBL] [Abstract][Full Text] [Related]
40. Neoadjuvant rituximab modulates the tumor immune environment in patients with high risk prostate cancer.
Ryan ST; Zhang J; Burner DN; Liss M; Pittman E; Muldong M; Shabaik A; Woo J; Basler N; Cunha J; Shalapour S; Estrada MV; Karin M; Messer K; Howell S; Kane CJ; Jamieson CAM
J Transl Med; 2020 May; 18(1):214. PubMed ID: 32466781
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
